Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
Public ClinicalTrials.gov record NCT03282240. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, modified double-blind, active-controlled, multi-center trial assessed the safety and immunogenicity of the high-dose quadrivalent influenza vaccine (QIV-HD) compared to either the licensed or investigational high-dose trivalent influenza vaccine (TIV-HD) in adults.
Study identification
- NCT ID
- NCT03282240
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,670 participants
Conditions and interventions
Conditions
Interventions
- QIV-HD Biological
- Licensed TIV-HD1 Biological
- Investigational TIV-HD2 Biological
Biological
Eligibility (public fields only)
- Age range
- 65 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 8, 2017 (Actual)
- Primary completion
- Nov 2, 2017 (Actual)
- Completion
- Apr 19, 2018 (Actual)
- Last update posted
- Apr 7, 2022
2017 – 2018
United States locations
- U.S. sites
- 36
- U.S. states
- 24
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sanofi Pasteur Investigational Site 037 | Anaheim | California | 92801 | — |
| Sanofi Pasteur Investigational Site 029 | Redding | California | 96001 | — |
| Sanofi Pasteur Investigational Site 003 | San Diego | California | 92117 | — |
| Sanofi Pasteur Investigational Site 016 | Colorado Springs | Colorado | 80920 | — |
| Sanofi Pasteur Investigational Site 035 | Milford | Connecticut | 06460 | — |
| Sanofi Pasteur Investigational Site 031 | Hollywood | Florida | 33024 | — |
| Sanofi Pasteur Investigational Site 009 | Jacksonville | Florida | 32205 | — |
| Sanofi Pasteur Investigational Site 017 | Jacksonville | Florida | 32216 | — |
| Sanofi Pasteur Investigational Site 030 | Stockbridge | Georgia | 30281 | — |
| Sanofi Pasteur Investigational Site 010 | Boise | Idaho | 83712 | — |
| Sanofi Pasteur Investigational Site 034 | Meridian | Idaho | 83642 | — |
| Sanofi Pasteur Investigational Site 021 | Council Bluffs | Iowa | 51501 | — |
| Sanofi Pasteur Investigational Site 023 | Wichita | Kansas | 67205 | — |
| Sanofi Pasteur Investigational Site 028 | Wichita | Kansas | 67207 | — |
| Sanofi Pasteur Investigational Site 012 | Bardstown | Kentucky | 40004 | — |
| Sanofi Pasteur Investigational Site 018 | Metairie | Louisiana | 70427 | — |
| Sanofi Pasteur Investigational Site 026 | Biloxi | Mississippi | 39531 | — |
| Sanofi Pasteur Investigational Site 014 | St Louis | Missouri | 63104 | — |
| Sanofi Pasteur Investigational Site 011 | Omaha | Nebraska | 68134 | — |
| Sanofi Pasteur Investigational Site 024 | Las Vegas | Nevada | 89104 | — |
| Sanofi Pasteur Investigational Site 008 | Rochester | New York | 14609 | — |
| Sanofi Pasteur Investigational Site 005 | Wilmington | North Carolina | 28401 | — |
| Sanofi Pasteur Investigational Site 036 | Winston-Salem | North Carolina | 27045 | — |
| Sanofi Pasteur Investigational Site 004 | Cleveland | Ohio | 44122 | — |
| Sanofi Pasteur Investigational Site 015 | Oklahoma City | Oklahoma | 73112 | — |
| Sanofi Pasteur Investigational Site 013 | Warwick | Rhode Island | 02886 | — |
| Sanofi Pasteur Investigational Site 033 | Mt. Pleasant | South Carolina | 29464 | — |
| Sanofi Pasteur Investigational Site 001 | Nashville | Tennessee | 37212 | — |
| Sanofi Pasteur Investigational Site 002 | Dallas | Texas | 75234 | — |
| Sanofi Pasteur Investigational Site 025 | Tomball | Texas | 77375 | — |
| Sanofi Pasteur Investigational Site 027 | Salt Lake City | Utah | 84109 | — |
| Sanofi Pasteur Investigational Site 006 | Salt Lake City | Utah | 84121 | — |
| Sanofi Pasteur Investigational Site 019 | Salt Lake City | Utah | 84123 | — |
| Sanofi Pasteur Investigational Site 020 | South Jordan | Utah | 84095 | — |
| Sanofi Pasteur Investigational Site 022 | West Jordan | Utah | 83642 | — |
| Sanofi Pasteur Investigational Site 038 | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03282240, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 7, 2022 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03282240 live on ClinicalTrials.gov.